Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Authors:
- 1 October 2018
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 130, 78-91
Abstract
No abstract availableKeywords
Funding Information
- Senhwa Biosciences, Inc
- Boston Biomedical, Inc
- Genentech, Taiho Pharmaceuticals
- Merck. Dr. Hubbard
This publication has 100 references indexed in Scilit:
- In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interactionProceedings of the National Academy of Sciences, 2013
- Progression of RAS-Mutant Leukemia during RAF Inhibitor TreatmentNew England Journal of Medicine, 2012
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie International Edition, 2012
- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewClinical Cancer Research, 2012
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityProceedings of the National Academy of Sciences, 2012
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeJNCI: Journal of the National Cancer Institute, 2012
- Identification and Characterization of a Novel Integrin-Linked Kinase InhibitorJournal of Medicinal Chemistry, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010